Header Logo

Connection

TERZAH HORTON to Humans

Back to Details
This is a "connection" page, showing publications TERZAH HORTON has written about Humans.
TERZAH HORTON
Connection Strength
0.469
Humans
  1. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072.
    View in: PubMed
    Score: 0.020
  2. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12).
    View in: PubMed
    Score: 0.019
  3. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060.
    View in: PubMed
    Score: 0.019
  4. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2021 02 20; 233:104046.
    View in: PubMed
    Score: 0.018
  5. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 07; 186(2):274-285.
    View in: PubMed
    Score: 0.016
  6. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res. 2018 08; 16(8):1263-1274.
    View in: PubMed
    Score: 0.015
  7. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul; 170(1):118-22.
    View in: PubMed
    Score: 0.012
  8. Yin and yang of glucocorticoid receptors in apoptosis. Blood. 2015 Jan 08; 125(2):209-11.
    View in: PubMed
    Score: 0.012
  9. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60.
    View in: PubMed
    Score: 0.012
  10. Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol. 2013 Aug; 35(6):456-61.
    View in: PubMed
    Score: 0.011
  11. Children are not large mice. Eur J Haematol. 2013 Jun; 90(6):535.
    View in: PubMed
    Score: 0.011
  12. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May; 170(5):555-9.
    View in: PubMed
    Score: 0.009
  13. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8.
    View in: PubMed
    Score: 0.009
  14. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42.
    View in: PubMed
    Score: 0.008
  15. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92.
    View in: PubMed
    Score: 0.008
  16. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8.
    View in: PubMed
    Score: 0.007
  17. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22.
    View in: PubMed
    Score: 0.007
  18. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23.
    View in: PubMed
    Score: 0.007
  19. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9.
    View in: PubMed
    Score: 0.006
  20. Cells and signals of the leukemic microenvironment that support progression of T-cell acute lymphoblastic leukemia (T-ALL). Exp Mol Med. 2024 Nov; 56(11):2337-2347.
    View in: PubMed
    Score: 0.006
  21. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
    View in: PubMed
    Score: 0.006
  22. Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia. Nat Commun. 2023 10 07; 14(1):6270.
    View in: PubMed
    Score: 0.006
  23. Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672.
    View in: PubMed
    Score: 0.006
  24. Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109.
    View in: PubMed
    Score: 0.005
  25. Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells. Blood Cancer Discov. 2023 05 01; 4(3):208-227.
    View in: PubMed
    Score: 0.005
  26. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9.
    View in: PubMed
    Score: 0.005
  27. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci. 2023 Mar 20; 24(6).
    View in: PubMed
    Score: 0.005
  28. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci. 2023 Mar 13; 24(6).
    View in: PubMed
    Score: 0.005
  29. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
    View in: PubMed
    Score: 0.005
  30. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343.
    View in: PubMed
    Score: 0.005
  31. IL-10 and TNFa are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. Pediatr Hematol Oncol. 2023 Mar; 40(2):147-158.
    View in: PubMed
    Score: 0.005
  32. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 07; 198(1):137-141.
    View in: PubMed
    Score: 0.005
  33. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 07 01; 40(19):2106-2118.
    View in: PubMed
    Score: 0.005
  34. A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. Blood. 2022 02 10; 139(6):889-893.
    View in: PubMed
    Score: 0.005
  35. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Expert Rev Proteomics. 2021 12; 18(12):1087-1097.
    View in: PubMed
    Score: 0.005
  36. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. Blood Adv. 2021 12 14; 5(23):4864-4876.
    View in: PubMed
    Score: 0.005
  37. Rational biomarker development for the early and minimally invasive monitoring of AML. Blood Adv. 2021 11 09; 5(21):4515-4520.
    View in: PubMed
    Score: 0.005
  38. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
    View in: PubMed
    Score: 0.005
  39. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clin Epigenetics. 2021 01 28; 13(1):21.
    View in: PubMed
    Score: 0.005
  40. Tumor-associated myeloid cells provide critical support for T-ALL. Blood. 2020 10 15; 136(16):1837-1850.
    View in: PubMed
    Score: 0.005
  41. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med. 2020 04 08; 12(538).
    View in: PubMed
    Score: 0.004
  42. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020 07; 105(7):1879-1886.
    View in: PubMed
    Score: 0.004
  43. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 02 03; 130(2):863-876.
    View in: PubMed
    Score: 0.004
  44. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
    View in: PubMed
    Score: 0.004
  45. Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche. EMBO Rep. 2019 07; 20(7):e47546.
    View in: PubMed
    Score: 0.004
  46. Transmissible ER stress reconfigures the AML bone marrow compartment. Leukemia. 2019 04; 33(4):918-930.
    View in: PubMed
    Score: 0.004
  47. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 09; 19(9):1229-1238.
    View in: PubMed
    Score: 0.004
  48. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Rev Proteomics. 2018 07; 15(7):613-622.
    View in: PubMed
    Score: 0.004
  49. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286.
    View in: PubMed
    Score: 0.004
  50. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999.
    View in: PubMed
    Score: 0.004
  51. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):355-364.
    View in: PubMed
    Score: 0.004
  52. Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3).
    View in: PubMed
    Score: 0.004
  53. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343.
    View in: PubMed
    Score: 0.004
  54. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017 12; 31(12):2568-2576.
    View in: PubMed
    Score: 0.004
  55. Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. J Clin Pharmacol. 2017 09; 57(9):1183-1193.
    View in: PubMed
    Score: 0.004
  56. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
    View in: PubMed
    Score: 0.004
  57. IDENTIFYING CANCER SPECIFIC METABOLIC SIGNATURES USING CONSTRAINT-BASED MODELS. Pac Symp Biocomput. 2017; 22:485-496.
    View in: PubMed
    Score: 0.004
  58. Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia. 2017 06; 31(6):1314-1324.
    View in: PubMed
    Score: 0.003
  59. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget. 2016 Nov 15; 7(46):74779-74796.
    View in: PubMed
    Score: 0.003
  60. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016 09 06; 9(1):82.
    View in: PubMed
    Score: 0.003
  61. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43.
    View in: PubMed
    Score: 0.003
  62. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer. 1996 Feb; 15(2):95-101.
    View in: PubMed
    Score: 0.003
  63. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74.
    View in: PubMed
    Score: 0.003
  64. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 1995 Oct; 45(10):1879-83.
    View in: PubMed
    Score: 0.003
  65. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15; 120(16):2482-9.
    View in: PubMed
    Score: 0.003
  66. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013 Dec; 98(12):1896-904.
    View in: PubMed
    Score: 0.003
  67. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7.
    View in: PubMed
    Score: 0.003
  68. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013 Jun; 60(6):972-8.
    View in: PubMed
    Score: 0.003
  69. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5.
    View in: PubMed
    Score: 0.003
  70. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.003
  71. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66.
    View in: PubMed
    Score: 0.002
  72. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012 Feb; 26(2):271-9.
    View in: PubMed
    Score: 0.002
  73. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 01; 55(6):1180-4.
    View in: PubMed
    Score: 0.002
  74. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009 Jul; 50(7):1174-82.
    View in: PubMed
    Score: 0.002
  75. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25.
    View in: PubMed
    Score: 0.002
  76. Development and validation of a fluorogenic assay to measure separase enzyme activity. Anal Biochem. 2009 Sep 15; 392(2):133-8.
    View in: PubMed
    Score: 0.002
  77. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5.
    View in: PubMed
    Score: 0.002
  78. Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. Apoptosis. 2006 Nov; 11(11):1977-86.
    View in: PubMed
    Score: 0.002
  79. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 01; 22(23):4804-9.
    View in: PubMed
    Score: 0.002
  80. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004 Nov; 145(5):617-21.
    View in: PubMed
    Score: 0.002
  81. Aseptic meningitis in a child after systemic treatment with high dose cytarabine. Pediatr Infect Dis J. 2001 Jan; 20(1):87-9.
    View in: PubMed
    Score: 0.001
  82. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim Biophys Acta. 1995 May 24; 1271(1):141-51.
    View in: PubMed
    Score: 0.001
  83. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 1994 Sep 15; 23(2):471-6.
    View in: PubMed
    Score: 0.001
  84. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992 Dec; 2(4):324-9.
    View in: PubMed
    Score: 0.001
  85. The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J Virol. 1991 Jun; 65(6):3083-94.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.